Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, discusses the single-arm prospective Phase II TUXEDO-1 (NCT04752059) trial investigating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive breast cancer and brain metastasis. The primary end point was intracranial response rate (RR) and a secondary endpoint was progression-free survival (PFS). Patients achieved a RR of 73.3% and a 14 month PFS was observed at 11 months median follow-up. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.
